This is a low-impact, non-binding exploratory collaboration announcement with no financial terms. Monitor for future definitive agreements or clinical evidence readouts that could validate expanded use of Telix's imaging agents. The insider buying is a modest positive but does not change the near-term outlook.
TLX drugs
TLX drug pipeline →- ◆ ITM-11 4/10 Phase 3 (completed)
- ● TLX591-Tx 4/10 Phase 3
- ● Zircaix 4/10 Phase 3 (ZIRCON) completed; BLA under FDA review
- ▲ Gozellix 3/10 Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2))
- ● TLX101-Tx 3/10 Phase 3 (pivotal, just initiated); Phase 1 safety stage complete
- All TLX drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 15 $10.56entry
- T+1 · 6mo ago −2.65%α −2.59% · $10.28
- T+5 · 6mo ago −10.32%α −11.29% · $9.47
- T+20 · 5mo ago −9.47%α −11.59% · $9.56
- T+60 · 3mo ago +13.64%α +9.12% · $12.00
Price Chart
How similar events traded
Executive Summary
Telix announced non-binding letters of intent to collaborate with EDAP TMS and Profound Medical, exploring the use of its PSMA-PET imaging agents (Gozellix and Illuccix) with robotic HIFU and TULSA ablation platforms for prostate cancer. The collaborations are early-stage, focused on scientific and educational research, with no financial terms disclosed and no immediate revenue impact.
Key Facts
- Telix entered letters of intent with EDAP TMS (Focal One robotic HIFU) and Profound Medical (TULSA-PRO MRI-guided ablation) for prostate cancer.
- Collaborations focus on investigational use of PSMA-PET imaging agents Gozellix and Illuccix for patient selection, treatment planning, and post-treatment monitoring.
- No financial terms, milestones, or revenue commitments were disclosed.
- PSMA-PET imaging is not currently approved for the specific treatment-planning indications explored in these collaborations.
- Telix's market cap is ~$3.7B; insider buying of ~$997K in the prior 30 days provides a modest positive signal.
Financial Impact
No financial terms disclosed; collaborations are non-binding and exploratory.
Risk Factors
- Collaborations are non-binding letters of intent, may not result in definitive agreements.
- PSMA-PET imaging is not yet approved for the specific treatment-planning indications explored.
- No revenue or financial impact expected in the near term.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295677 |
Track record
27 reports on TLX
10 of 21 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 19 of 21 went positive at some point.
Filters
- Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
- Oct 20, 202627d ago 6-K Neutral 4/10 No price data
- Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
- Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
- Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
- Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers